ABSTRACT
INTRODUCTION

Biopharmaceutics classification system (BCS)
Biopharmaceutics classification system classifies drugs according to their solubility in water and membrane per-
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meability into four classes described in Table 1 . Drugs included in the BCS II class are generally classified as drugs with low solubility but high permeability. These drug little dissolve during their passage through the gastrointestinal (GI) tract [13] and therefore are not completely absorbed.
Their bioavailability is therefore limited by their low solubility in water which means that even a small increase in solubility may result in considerable increase in bioavailability [6] . With preliminary dissolution of such drugs in lipids, surfactants or their mixtures we can avoid to the dissolution step which limits absorption of these drugs from the GI tract [2] . It is important to achieve adequate absorption from the water environment. This is the reason why stress is laid on the potential of excipients to produce spontaneous emulsions and form micro-or nano-droplets. 
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Formulations
Lipid-Based delivery systems range from simple oil solutions to complex mixtures of oils, surfactants and cosolvents [8] . They have a high potential for increasing solu- bility of BCS class II drugs. Drugs in LBF are already in a soluble form and thus the dissolution step is omitted in the GI tract. Moreover, these formulations should be able to form emulsions in the water environment and maintain the drug in the solubilized state without its precipitation. In the GI tract, the LBF systems increase absorption of drugs by accelerating the dissolution process facilitating the formation of solubilised phases by reduction the particle size to the molecular level [3, 9] changing drug uptake, efflux and disposition by altering enterocyte-based transport, [11, 14] and enhancing drug transport to the systemic circulation via intestinal lymphatic system [1, 4, 10] .
The aim of the study was to identify a limited series (mixtures of) excipients that can be used for oral administration of a range of structurally different poorly water soluble drugs and study their potential as simplified strategy formulation.
Toxicity of excipients
Excipients are essential components of drug products.
They may be also potential toxicants. Examples of known excipients-induced toxicities include renal failure and death caused by diethylene glycol, or cardiotoxicity induced by propylene glycol [7] . Safety of excipients used in this proj- 
MATERIAL AND METHODS
The following additives were tested: XA, Xf, Xg, Xh, XB, 
Preparation of formulations
The selected excipients were warmed up in a water bath at 55 °C for 5-10 min and homogenised. Required quantities of the relevant excipients were weighed into serum bottles (20 ml) and mixed (magnetic mixer, 300 rpm) for 15 min in a water bath. After mixing the stirring bar was removed, nitrogen was introduced into bottles and the bottles were closed.
Emulsification potential -water, FaSSGF and FaSSIF
(Fasted State Simulated Gastric and Intestinal Fluid)
Behaviour was observed at laboratory temperature. 
UPLC screening
For the screening were prepared 100 ml solutions of formulations (7 µl.ml 
Maximum saturation
The experiment was carried out in duplicate. Five ml of formulation was added into a glass 10 ml bottle containing 125 mg of the API and the stirring bar. The content was mixed at 350 rpm for 20 hours at 50 °C. Subsequently, the mixing was continued at laboratory temperature at 100 rpm for 20 hours. If the drug dissolved completely, additional quantity of drug was added and the procedure was repeated. Analysis was carried out using 1 ml of sample withdrawn by means of a 2 ml syringe.
The sample was filtered into a HPLC bottle through GHP Acrodisc® 13 mm syringe filter equipped with 0.2 µm GHP membrane and was diluted with tetrahydrofuran to a required concentration. Fresh reference standards were prepared by weighing accurate amounts of drugs and dissolving it in THF. THF was used as a blank. Then, 1 µl of sample was injected to Waters Acquity UPLC ® System using Method 13.
RESULTS AND DISCUSSION
Formulations
Series of formulations were prepared (A, B, C, E, F)
and their physical properties (viscosity, phase, homogeneity, colour) were described. To each of the formulations a factor was assigned according to rotational speed which resulted in formation of emulsion and this factor together with the stability and degree of dispersity were the main criteria for selection of formulations for subsequent study.
Several formulations were unstable, e.g. the phases separated in water environment. Also some of them exhibited inadequate emulsification potential and degree of dispersity. In this way we were able to reduce the number of prospective formulations.
The following formulations were selected for studies in FaSSGF and FaSSIF (Fasted State Simulated Gastric and Intestinal Fluid): A1; A2; A3; A8; A9; B3; B4; C2; C3; C9; C13; E7; F4−F11.
The following formulations were selected for studies of maximum saturation: A2; A8; B3; F5; F7; F8; F10; F11.
Waters Acquity UPLC screening method
All drugs and excipients were analysed using Method 1 and Method 13 (Waters Acquity UPLC ® System). These methods differ in the length of analysis. The longer Method 13 appeared more suitable for all drugs and excipients. On the basis of UV spectra of individual drugs (Fig. 3) we selected optimum wavelength for analysis of additional samples at their saturation. Fig. 4 illustrates relative solubility of drugs in tested formulations. As the maximum solubility of drugs in individual formulations differed (see Table 3 ), a factor 1 was , respectively. Griseofulvine and Itraconazol in A8: 10.2 mg.ml -1 and 3.3 mg.ml -1 , respectively.
Maximum saturation
The highest concentration of Triclosan was reached in F5: . Formulation G4 was experimental and was not mentioned in materials and methods above.
The solubility of drugs in the selected formulations was increased considerably and with some formulations was higher by several orders of magnitude in comparison with their solubility in water (Table 3) . 
CONCLUSION
